Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Senti Biosciences, Inc. - Common Stock (NQ:SNTI)

3.100 +0.130 (+4.38%)
Streaming Delayed Price Updated: 10:39 AM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Senti Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024 
From Senti Biosciences, Inc.
Via GlobeNewswire
Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices. 
Via MarketBeat
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia 
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio to Participate in Upcoming Conferences
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio to Participate in Upcoming Investor Conferences
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages 
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio to Participate in Upcoming Investor Conferences
From Senti Biosciences, Inc.
Via GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Senti Biosciences Announces New Employment Inducement Grants
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio to Present at the SVB Securities Global Biopharma Conference
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.